{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:44:04Z","timestamp":1786196644194,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20-GM125507"],"award-info":[{"award-number":["P20-GM125507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["F31DA061593"],"award-info":[{"award-number":["F31DA061593"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.josat.2026.210051","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:16:13Z","timestamp":1781208973000},"page":"210051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Healthcare provider approaches to managing the health harms of xylazine: A qualitative study"],"prefix":"10.1016","volume":"190","author":[{"given":"Patrick J.A.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiah D.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie B.","family":"Biello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D.L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.W.","family":"Hughto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2026.210051_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/29767342231214472","article-title":"Xylazine-associated wounds and related health concerns among people who use drugs: Reports from front-line health workers in 7 US states","author":"Carroll","year":"2024","journal-title":"Substance Use &amp; Addiction Journal"},{"key":"10.1016\/j.josat.2026.210051_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.rcsop.2021.100029","article-title":"A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder","volume":"2","author":"Cernasev","year":"2021","journal-title":"Exploratory Research in Clinical and Social Pharmacy"},{"key":"10.1016\/j.josat.2026.210051_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104118","article-title":"Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island","volume":"118","author":"Collins","year":"2023","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2026.210051_bb0020","doi-asserted-by":"crossref","DOI":"10.1177\/87551225251326811","article-title":"Standard instructions and counseling for naloxone insufficient in the era of xylazine and medetomidine adulteration of illicit opioids","author":"Datta","year":"2025","journal-title":"Journal of Pharmacy Technology"},{"issue":"10","key":"10.1016\/j.josat.2026.210051_bb0025","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin\u2013fentanyl drug supply","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.josat.2026.210051_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001198","article-title":"Recognition and treatment of wounds in persons using Xylazine: A case report from New Haven, Connecticut","author":"Dowton","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.210051_bb0035","unstructured":"Drug Enforcement Agency. (n.d.). DEA reports widespread threat of fentanyl mixed with Xylazine | DEA.gov. DEA.Gov. Retrieved March 28, 2025, from https:\/\/www.dea.gov\/alert\/dea-reports-widespread-threat-fentanyl-mixed-xylazine."},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12954-024-01082-y","article-title":"Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration","volume":"21","author":"Eger","year":"2024","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2026.210051_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210051_bb0050","author":"Hamilton"},{"issue":"4","key":"10.1016\/j.josat.2026.210051_bb0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1049732316665344","article-title":"Code saturation versus meaning saturation: How many interviews are enough?","volume":"27","author":"Hennink","year":"2017","journal-title":"Qualitative Health Research"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0060","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12954-024-01052-4","article-title":"Providers\u2019 knowledge and perception of xylazine in the unregulated drug supply: A sequential explanatory mixed-methods study","volume":"21","author":"Hill","year":"2024","journal-title":"Harm Reduction Journal"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0065","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/epirev\/mxaa011","article-title":"The evolving overdose epidemic: Synthetic opioids and rising stimulant-related harms","volume":"42","author":"Jones","year":"2020","journal-title":"Epidemiologic Reviews"},{"key":"10.1016\/j.josat.2026.210051_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111375","article-title":"Empirical assessment of wounds among people who use substances","author":"Jones","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/08897077.2020.1748165","article-title":"\u201cNarcan encounters:\u201d Overdose and naloxone rescue experiences among people who use opioids","volume":"43","author":"Kahn","year":"2022","journal-title":"Substance Abuse"},{"issue":"2","key":"10.1016\/j.josat.2026.210051_bb0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/29767342241289797","article-title":"Psychosocial impact of suspected xylazine-associated skin wounds among people using fentanyl, Philadelphia, 2022 to 2023","volume":"46","author":"Kelly","year":"2025","journal-title":"Substance Use & Addiction Journal"},{"key":"10.1016\/j.josat.2026.210051_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2024.08.036","article-title":"Tranq dope: Characterization of an ED cohort treated with a novel opioid withdrawal protocol in the era of fentanyl\/Xylazine","author":"London","year":"2024","journal-title":"The American Journal of Emergency Medicine."},{"key":"10.1016\/j.josat.2026.210051_bb0090","article-title":"Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA","author":"Malayala","year":"2022","journal-title":"Cureus Journal of Medical Science"},{"key":"10.1016\/j.josat.2026.210051_bb0095","series-title":"Managing patients taking xylazine-adulterated opioids in emergency, hospital, and addiction care settings","author":"National Institute on Drug Abuse","year":"2023"},{"key":"10.1016\/j.josat.2026.210051_bb0100","series-title":"StatPearls","article-title":"Xylazine toxicity","author":"Papudesi","year":"2025"},{"key":"10.1016\/j.josat.2026.210051_bb0105","author":"Philadelphia Department of Public Health"},{"key":"10.1016\/j.josat.2026.210051_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104154","article-title":"Xylazine in the drug supply: Emerging threats and lessons learned in areas with high levels of adulteration","volume":"120","author":"Quijano","year":"2023","journal-title":"International Journal of Drug Policy"},{"issue":"2","key":"10.1016\/j.josat.2026.210051_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-251082","article-title":"Soft tissue infection and follow-up for an unsheltered patient: The role of Street Medicine providers in bridging gaps in care","volume":"16","author":"Rasul","year":"2023","journal-title":"BMJ Case Reports"},{"key":"10.1016\/j.josat.2026.210051_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2024.209509","article-title":"Patient and navigator experiences with the opioid use disorder treatment system in Philadelphia, PA","author":"Reed","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0125","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/10826084.2024.2409720","article-title":"Xylazine\u2019s impacts on the community in Philadelphia: Perspectives of people who use opioids and harm reduction workers","volume":"60","author":"Reed","year":"2025","journal-title":"Substance Use & Misuse"},{"key":"10.1016\/j.josat.2026.210051_bb0130","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7217a2","article-title":"Rapid analysis of drugs: A pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses \u2014 Eight syringe services programs, Maryland, November 2021\u2013August 2022","volume":"72","author":"Russell","year":"2023","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.josat.2026.210051_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/29767342251329681","article-title":"Building multidisciplinary consensus on inpatient xylazine management through clinical protocols","author":"Shang","year":"2025","journal-title":"Substance Use & Addiction Journal"},{"key":"10.1016\/j.josat.2026.210051_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/dar.70024","article-title":"Emergence of medetomidine in the unregulated drug supply and its association with hallucinogenic effects","author":"Sibley","year":"2025","journal-title":"Drug and Alcohol Review"},{"issue":"8","key":"10.1016\/j.josat.2026.210051_bb0145","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/10826084.2025.2491768","article-title":"\"All you can do is what you know to do\": Naloxone knowledge and uncertainty among people who use drugs in Maryland amid a volatile drug market","volume":"60","author":"Sisson","year":"2025","journal-title":"Substance Use Misuse"},{"key":"10.1016\/j.josat.2026.210051_bb0150","article-title":"Necrotic upper-extremity infections in people who inject drugs: A case series","author":"Soderquist","year":"2023","journal-title":"The Journal of Hand Surgery"},{"issue":"4","key":"10.1016\/j.josat.2026.210051_bb0155","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/add.16388","article-title":"Clinical considerations for the management of xylazine overdoses and xylazine-related wounds","volume":"119","author":"Sue","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.210051_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112681","article-title":"Manifestations of potential xylazine withdrawal: A retrospective cohort study with nested case series","author":"Thakrar","year":"2025","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210051_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2024.100241","article-title":"Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods","author":"Thompson","year":"2024","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"6","key":"10.1016\/j.josat.2026.210051_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"International Journal for Quality in Health Care"},{"key":"10.1016\/j.josat.2026.210051_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/dar.70037","article-title":"Point-of-care drug-checking: Assessing the Rhode Island drug supply using FTIR spectroscopy to detect fentanyl, xylazine and other substances","author":"Ujeneza","year":"2025","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12954-024-00978-z","article-title":"A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA","volume":"21","author":"Warp","year":"2024","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2026.210051_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2023.04.016","article-title":"Severe cutaneous ulcerations secondary to xylazine (tranq): A case series","volume":"36","author":"Wei","year":"2023","journal-title":"JAAD Case Reports"},{"issue":"S6","key":"10.1016\/j.josat.2026.210051_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.GOX.0001024456.83549.92","article-title":"The Spectrum of bone and soft tissue destruction in deso-morphine and xyalzine use disorder","volume":"12","author":"Zabel","year":"2024","journal-title":"Plastic and Reconstructive Surgery. Global Open"},{"issue":"1","key":"10.1016\/j.josat.2026.210051_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","article-title":"Reducing the harms of xylazine: Clinical approaches, research deficits, and public health context","volume":"20","author":"Zagorski","year":"2023","journal-title":"Harm Reduction Journal"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:30:05Z","timestamp":1786195805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926001712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S2949875926001712"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210051","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare provider approaches to managing the health harms of xylazine: A qualitative study","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"210051"}}